Stock Updates

A look at a High Market Cap Stock: Regeneron Pharmaceuticals, Inc., REGN

Regeneron Pharmaceuticals, Inc., REGN is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in USA, Regeneron Pharmaceuticals, Inc., REGN  has a market cap of 42274. Since its IPO date on the 4/2/1991, Regeneron Pharmaceuticals, Inc., REGN performance year to date is -26.83%. Today Regeneron Pharmaceuticals, Inc., REGN has gained -1.40%, with a current price of 397.2.

Ownership of the company is 0.50% for insider ownership while institutional ownership is 70.90%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 13.00%, with return on investment at 16.00%.

In terms of debt levels and profit levels, Regeneron Pharmaceuticals, Inc., REGN is seeing a long-term debt/equity of 0.09. While Total debt/equity is 0.09. With a profit margin of 16.00%, this is combined with a gross margin of 91.40%, and operating margin of 26.70%. Regeneron Pharmaceuticals, Inc. ability to meet debt levels, with a current ratio of 3.4, while the quick ratio is 3.1.

For the last year Regeneron Pharmaceuticals, Inc., REGN has seen a EPS growth of 85.10%. A performance for the year of -16.05%. The 52-week high is -32.97%, and the 52-week low is 20.70%. The average volume for Regeneron Pharmaceuticals, Inc., REGN is 557100.

With a target price of 467.86, can Regeneron Pharmaceuticals, Inc., REGN reach this target? Looking at the value indicators of Regeneron Pharmaceuticals, Inc., REGN. Regeneron Pharmaceuticals, Inc. has a P/E of 62 and a forward P/E of 27.35. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.33. Regeneron Pharmaceuticals, Inc. also has a P/S and a P/B of 9.09 and 10.2 respectively. For P/cash, Regeneron Pharmaceuticals, Inc. has a value of 40.45, while it is 40.17 for P/free cash flow.

At the current price of 397.2, Regeneron Pharmaceuticals, Inc. has a dividend yield of *TBA. We see a return on equity of 20.10%.

Looking more long-term Regeneron Pharmaceuticals, Inc., is projected to get an EPS growth for the next five years of 18.62%. In the short-term an EPS growth of 32.01% in the next year is forecasted. This is after a EPS growth of 85.10% for this year and for the last five years a 44.90% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Mark Hines

Leave a Comment